

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

761270Orig1s000

Trade Name: Imjudo injection

Generic or Proper Name: tremelimumab-actl

Sponsor: AstraZeneca AB

Approval Date: November 10, 2022

Indication: Imjudo is indicated, in combination with durvalumab and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

CENTER FOR DRUG EVALUATION AND RESEARCH

761270Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Officer/Employee List	X
Multidiscipline Review(s) <ul style="list-style-type: none">• Summary Review• Clinical• Non-Clinical• Statistical• Clinical Pharmacology	X
Product Quality Review(s)	X
Clinical Microbiology / Virology Review(s)	
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

761270Orig1s000

APPROVAL LETTER

BLA 761270

BLA APPROVAL

AstraZeneca AB
Attention: Martin Mao, M.S., RAC
Regulatory Affairs Director
AstraZeneca Pharmaceuticals, LP
One MedImmune Way
Gaithersburg, MD 20878

Dear Mr. Mao:

Please refer to your biologics license application (BLA) dated November 12, 2021, received November 15, 2021, and your amendments, submitted under section 351(a) of the Public Health Service Act for Imjudo (tremelimumab-actl) injection.

LICENSING

We have approved your BLA for Imjudo (tremelimumab-actl) effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Imjudo under your existing Department of Health and Human Services U.S. License No. 2059. Imjudo is indicated, in combination with durvalumab and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture Imjudo drug substance at [REDACTED] (b) (4). The final formulated drug product will be manufactured and filled at [REDACTED] (b) (4) and labeled and packaged at AstraZeneca AB, Södertälje, Sweden. You may label your product with the proprietary name, Imjudo, and market it in 25 mg/1.25 mL (20 mg/mL) solution in a single-dose vial or 300 mg/15 mL (20mg/mL) solution in a single-dose vial.

DATING PERIOD

The dating period for Imjudo shall be 48 months from the date of manufacture when stored at 2-8°C. The date of manufacture shall be defined as the date of final sterile filtration of the formulated drug product. The dating period for your drug substance shall be a total of [REDACTED] (b) (4) months from the date of manufacture [REDACTED] (b) (4).

FDA LOT RELEASE

You are not currently required to submit samples of future lots of Imjudo to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Imjudo, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As (October 2009)*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on November 9, 2022, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission "**Final Printed Carton**

¹ See <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

and Container Labeling for approved BLA 761270.” Approval of this submission by FDA is not required before the labeling is used.

ADVISORY COMMITTEE

Your application for Imjudo was not referred to an FDA advisory committee because the application did not raise significant safety or efficacy issues that were unexpected in the intended population.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because necessary studies are impossible or highly impracticable due to the rarity of the condition in children.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

- 4364-1 To perform a shipping validation study under real time shipping conditions (i.e. temperature, mode of transport, shipping duration, and shipping containers and packing representative of the minimum and maximum load) using a representative commercial tremelimumab drug product lot in the final commercial container closure and packaging systems to evaluate the ability of the shipping containers to maintain the recommended temperature and to evaluate the impact of shipping from the AstraZeneca Sweden labeling and packaging site to the US Distribution Center on the physical integrity and product quality of tremelimumab drug product. The shipping validation data will be submitted in accordance with 21 CFR 601.12.

The timetable you submitted on August 9, 2022, states that you will conduct this study according to the following schedule:

Final Report Submission: 12/2023

4364-2 Implement (b) (4) monitoring (b) (4) validated by the microbial retention study.

The timetable you submitted on May 31, 2022, states that you will conduct this study according to the following schedule:

Final Report Submission: 12/2023

Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this BLA. In addition, under 21 CFR 601.70 you should include a status summary of each commitment in your annual progress report of postmarketing studies to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients/subjects entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol**,” “**Postmarketing Commitment Final Report**,” or “**Postmarketing Commitment Correspondence**.”

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements at 21 CFR 600.80.

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

You must submit distribution reports under the distribution reporting requirements at 21 CFR 600.81.

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

We have now administratively closed this BLA. Therefore, carton and container final printed labeling (if requested above), all 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, promotional materials and other submissions should be addressed to the parent **BLA 761289** for this product, not to this BLA. **In the future, do not make submissions to this BLA.**

If you have any questions, call Idara Ojofeitimi, Chief, Project Management Staff, at 301-796-3074.

Sincerely,

{See appended electronic signature page}

Harpreet Singh, M.D.
Director
Division of Oncology 2
Office of Oncologic Diseases
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

BONNIE HARPREET MOORE
11/10/2022 02:59:21 PM